Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 2
- Pillar Clinical Research - Bentonville · Bentonville, AR
- Pillar Clinical Research- Little Rock · Little Rock, AR
Florida · 2
- Research Centers of America ( Hollywood ) · Hollywood, FL
- Health Synergy Clinical Research · West Palm Beach, FL
Georgia · 1
- Atlanta Center for Medical Research · Atlanta, GA
Illinois · 1
- Pillar Clinical Research -Chicago · Chicago, IL
Texas · 1
- Pillar Clinical Research - Richardson · Richardson, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.